Literature DB >> 30537507

Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally.

Jessie A Brown1, Adolfo Ferrando2.   

Abstract

Glucocorticoid resistance represents a major challenge in treating acute lymphoblastic leukemia. In this issue of Cancer Cell, Jing and colleagues show epigenetic deregulation of glucocorticoid-induced BIM activation in glucocorticoid-resistant leukemia cells, and restore glucocorticoid-receptor-induced BIM upregulation with DNA demethylating agents to effectively enhance glucocorticoid response.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30537507     DOI： 10.1016/j.ccell.2018.11.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  7 in total

1.  JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.

Authors:  Aissa Benyoucef; Katharina Haigh; Andrew Cuddihy; Jody J Haigh
Journal:  Leukemia       Date:  2022-10-13       Impact factor: 12.883

2.  Association Between NR3C1 Mutations and Glucocorticoid Resistance in Children With Acute Lymphoblastic Leukemia.

Authors:  Haiyan Liu; Ziping Li; Fei Qiu; Chunjie Li; Xiaojing Lin; Yingyi He; Maoxiang Qian; Yuanbin Song; Hui Zhang
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

3.  Effects of NRAS Mutations on Leukemogenesis and Targeting of Children With Acute Lymphoblastic Leukemia.

Authors:  Jiabi Qian; Zifeng Li; Kunlin Pei; Ziping Li; Chunjie Li; Muxia Yan; Maoxiang Qian; Yuanbin Song; Hui Zhang; Yingyi He
Journal:  Front Cell Dev Biol       Date:  2022-02-08

4.  LRH-1/NR5A2 interacts with the glucocorticoid receptor to regulate glucocorticoid resistance.

Authors:  Svenja Michalek; Thomas Goj; Anna Pia Plazzo; Blerim Marovca; Beat Bornhauser; Thomas Brunner
Journal:  EMBO Rep       Date:  2022-07-08       Impact factor: 9.071

5.  Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways.

Authors:  Miriam Butler; Britt M T Vervoort; Dorette S van Ingen Schenau; Lieneke Jongeneel; Jordy C G van der Zwet; René Marke; Jules P P Meijerink; Blanca Scheijen; Laurens T van der Meer; Frank N van Leeuwen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

6.  miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway.

Authors:  Marianna Lucafò; Daria Sicari; Andrea Chicco; Debora Curci; Arianna Bellazzo; Alessia Di Silvestre; Chiara Pegolo; Robert Autry; Erika Cecchin; Sara De Iudicibus; Licio Collavin; William Evans; Giuliana Decorti; Gabriele Stocco
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-10       Impact factor: 3.333

Review 7.  Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia.

Authors:  Krzysztof Jędraszek; Marta Malczewska; Karolina Parysek-Wójcik; Monika Lejman
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.